The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Malignant glioma: genetics and biology of a grave matter
Open accessAbstract
Malignant brain tumors strike deep into the psyche of those receiving and those delivering the diagnosis. Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors considered to be among the deadliest of human cancers. In its most aggressive manifestation, glioblastoma (GBM), median survival ranges from 9 to 12 months, despite maximum treatment efforts—a statistical fact that has changed little over several decades of technological advances in neurosurgery, radiation therapy, and clinical trials of conventional and novel therapeutics. Over the same time period, there has been an explosion of knowledge in cancer biology and basic science discovery that has fueled meaningful progress in the treatment of many common human cancers, including those of the breast, lung, and prostate. It is perplexing that therapies used effectively in the treatment of these solid tumors are overwhelmingly ineffective in the treatment of GBM, perhaps reflecting the eccentric biology and cellular origin of this neoplasm. To date, only one new agent has been documented to have modest activity against intermediate-grade gliomas, whereas no effective agents have emerged for the treatment of GBM, despite 20 years of enrolling patients in clinical trials. It is ironic that although a comprehensive view of the genetic lesions encountered in malignant gliomas has been compiled, substantive conceptual and practical barriers remain in assigning functional significance to these genetic changes and in harnessing this basic information into the development of drugs that make a difference in patient care. The history of treating malignant gliomas dates back to the middle of the 19th century and parallels landmark advances in modern surgical technique and the clinical discipline of neurology. The first brain tumor surgery of the modern era was performed in 1884 by Rickman
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 2×
“In the quiescent cell, pRB is in its hypophosphorylated state bound to E2F, preventing transcription of genes important for mitosis and thus preventing progression through the G1/S restriction point (for review, see Sherr 1996).”
BackgroundLi, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Reynolds, B. A., & Weiss, S. (1992) · Science · doi:10.1126/science.1553558 · Cited by 4,482
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“MDM2 inhibits p53 transcriptional activity directly by binding to the N-terminal transactivation domain and also functions as an E3 ubiquitin ligase, serving a critical role in the ubiquitination and proteosomal degradation of p53 (Momand et al. 1992; Haupt et al. 1997; Kubbutat et al. 1997).”
BackgroundMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Research works printed but not linked: 25
- Al-Awqati, 1999, Terminal differentiation in epithelia: The Hensin pathway in intercalated cells., Semin. Nephrol., 19, 415
- Biernat, 1995, Identical mutations of the p53 tumor supressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells., J. Neuropathol. Exp. Neurol., 54, 651, 10.1097/00005072-199509000-00006 · doi:10.1097/00005072-199509000-00006
- Bouchard, 1960, Radiation therapy in the management of neoplasms of the central nervous system, with a special note in regard to children: Twenty years experience., Am. J. Roentgenol., 84, 610
- 10.1016/0006-8993(85)90802-9 · doi:10.1016/0006-8993(85)90802-9
- 10.1002/(SICI)1097-4547(19980901)53:5<521::AID-JNR2>3.0.CO;2-B · doi:10.1002/(sici)1097-4547(19980901)53:5<521::aid-jnr2>3.0.co;2-b
- 10.1006/exnr.2000.7482 · doi:10.1006/exnr.2000.7482
- 10.1046/j.1471-4159.2000.0741393.x · doi:10.1046/j.1471-4159.2000.0741393.x
- Heldin, 1996, Protein tyrosine kinase receptors., Cancer Surveys, 27, 7
- 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1 · doi:10.1002/(sici)1098-2264(199805)22:1<9::aid-gcc2>3.0.co;2-1
- James, 1991, Chromosome 9 deletion mapping reveals interferon α and interferon β-1 gene deletions in human glial tumors., Cancer Res., 51, 1684
- McKeever, 1991, Patterns of antigenic expression of human glioma cells., Crit. Rev. Neurobiol., 6, 119
- 10.1002/(SICI)1098-1136(199701)19:1<85::AID-GLIA9>3.0.CO;2-9 · doi:10.1002/(sici)1098-1136(199701)19:1<85::aid-glia9>3.0.co;2-9
- Mishima, K., Nagane, M., Lin, H., Cavenee, W., and Huang, H.J.S. 1999. Expression of a specific mutant epidermal growth factor receptor mediates glioma cell invasion in vivo. Proc. Am. Assoc. Cancer Res.: 519..
- 10.1007/BF00713052 · doi:10.1007/bf00713052
- Mueller, 2001, Clonal analysis in glioblastoma with epithelial differentation., Brain Pathol., 11, 39, 10.1111/j.1750-3639.2001.tb00379.x · doi:10.1111/j.1750-3639.2001.tb00379.x
- Quelle, 1995, Cloning and characterization of murine p16INK4a and p15INK4b genes., Oncogene, 11, 635
- Rubio, 1994, Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas., Cancer Res., 54, 45
- 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U · doi:10.1002/(sici)1521-1878(199810)20:10<808::aid-bies6>3.0.co;2-u
- 10.1002/(SICI)1098-1136(199903)26:1<22::AID-GLIA3>3.0.CO;2-M · doi:10.1002/(sici)1098-1136(199903)26:1<22::aid-glia3>3.0.co;2-m
- Small R.K. (1992) Glial cell lineages in development and disease. in Disease of the nervous system: Clinical Neurobiology, eds Ashurry A.K. McKhann G.M. McDonald W.I. (W.B. Saunders Company, Philadelphia), pp 72–86.
- Smith, J.S., Tachibana, I., Pohl, U., Lee, H.K., Thanarajasigam, U., Portier, B.P., Ueki, K., Ramaswamy, S., Billings, S.J., Mohrenweiser, H.W., et al. 2000. A transcript map of the chromosome 19 q-arm tumor supressor region. Genomics , in press.. · doi:10.1006/geno.1999.6101
- Takito, 1999, Hensin, the polarity reversal protein, is encoded by DMBT1, a gene frequently deleted in malignant gliomas., Am. J. Physiol., 277, F277
- Tsai, 2000, Cell contact regulates fate choice by cortical stem cells., J. Neurosci., 20, 3725, 10.1523/JNEUROSCI.20-10-03725.2000 · doi:10.1523/jneurosci.20-10-03725.2000
- 10.1002/(SICI)1097-0215(20000201)85:3<398::AID-IJC17>3.0.CO;2-L · DOI
- 10.1006/geno.1995.9972 · doi:10.1006/geno.1995.9972
Cited by
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.030 · Cited by 2,311
Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Sımjee, S. U. (2017) · PubMed · doi:10.22034/apjcp.2017.18.1.3 · Cited by 1,231
G1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment
Giese, A., Bjerkvig, R., Berens, M. E., & Westphal, M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.063 · Cited by 1,200
Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,075
Neural Stem Cells and the Origin of Gliomas
Sanai, N., Alvarez-Buylla, A., & Berger, M. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043666 · Cited by 1,044
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Self-citationPrimary brain tumours in adults
Behin, A., Hoang-Xuan, K., Carpentier, A. F., & Delattre, J.-Y. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12328-8 · Cited by 754
Gli and hedgehog in cancer: tumours, embryos and stem cells
Ruiz i Altaba, A., Sánchez, P., & Dahmane, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc796 · Cited by 708
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Alcantara Llaguno, S., Chen, J., Kwon, C.-H., Jackson, E. L., Li, Y., Burns, D. K., Alvarez-Buylla, A., & Parada, L. F. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.006 · Cited by 694
MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS
Louis, D. N. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100043 · Cited by 648
Self-citationCyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma
Bar, E. E., Chaudhry, A., Lin, A., Fan, X., Schreck, K., Matsui, W., Piccirillo, S., Vescovi, A. L., DiMeco, F., Olivi, A., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0166 · Cited by 607
Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis
Sierra, A., Abiega, O., Shahraz, A., & Neumann, H. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00006 · Cited by 574
Cancer stem cells in nervous system tumors
Singh, S. K., Clarke, I. D., Hide, T., & Dirks, P. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207946 · Cited by 569
Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D. K., Mason, R. P., Messing, A., & Parada, L. F. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.004 · Cited by 550
Inda, M.-D.-M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W. Y., Vandenberg, S., Brennan, C., Johns, T. G., Bachoo, R., Hadwiger, P., et al. (2010) · Genes & Development · doi:10.1101/gad.1890510 · Cited by 543
Self-citationBrennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A., & Holland, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007752 · Cited by 534
Peñuelas, S., Anido, J., Prieto-Sánchez, R. M., Folch, G., Barba, I., Cuartas, I., García-Dorado, D., Poca, M. A., Sahuquillo, J., Baselga, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.011 · Cited by 526
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
Ligon, K. L., Huillard, E., Mehta, S., Kesari, S., Liu, H., Alberta, J. A., Bachoo, R. M., Kane, M., Louis, D. N., DePinho, R. A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.009 · Cited by 501
Self-citationBruna, A., Darken, R. S., Rojo, F., Ocaña, A., Peñuelas, S., Arias, A., Paris, R., Tortosa, A., Mora, J., Baselga, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.023 · Cited by 472
INK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442
The Cytoskeleton—A Complex Interacting Meshwork
Hohmann, T., & Dehghani, F. (2019) · Cells · doi:10.3390/cells8040362 · Cited by 449
Lim, D. A., Cha, S., Mayo, M. C., Chen, M.-H., Keles, E., VandenBerg, S., & Berger, M. S. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-023 · Cited by 442
The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas
Ligon, K. L., Alberta, J. A., Kho, A. T., Weiss, J., Kwaan, M. R., Nutt, C. L., Louis, D. N., Stiles, C. D., & Rowitch, D. H. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.5.499 · Cited by 438
Self-citationWen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Self-citationEichhorn, P. J. A., Rodón, L., Gonzàlez-Juncà, A., Dirac, A., Gili, M., Martínez-Sáez, E., Aura, C., Barba, I., Peg, V., Prat, A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2619 · Cited by 409
Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705158104 · Cited by 390
Self-citationRahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Guo, P., Hu, B., Gu, W., Xu, L., Wang, D., Huang, H.-J. S., Cavenee, W. K., & Cheng, S.-Y. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63905-3 · Cited by 367
Self-citationThe candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis
Garkavtsev, I., Kozin, S. V., Chernova, O., Xu, L., Winkler, F., Brown, E., Barnett, G. H., & Jain, R. K. (2004) · Nature · doi:10.1038/nature02329 · Cited by 353
Development of a novel mouse glioma model using lentiviral vectors
Marumoto, T., Tashiro, A., Friedmann-Morvinski, D., Scadeng, M., Soda, Y., Gage, F. H., & Verma, I. M. (2009) · Nature Medicine · doi:10.1038/nm.1863 · Cited by 353
Candolfi, M., Curtin, J. F., Nichols, W. S., Muhammad, A. G., King, G. D., Pluhar, G. E., McNiel, E. A., Ohlfest, J. R., Freese, A. B., Moore, P. F., et al. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9400-9 · Cited by 351
Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G. N., Khan, A., Conrad, C. A., Liu, T.-J., Jiang, H., Lemoine, M. G., Suzuki, K., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.652 · Cited by 350
The molecular profile of microglia under the influence of glioma
Li, W., & Graeber, M. B. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos116 · Cited by 340
Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma
Chen, P., Zhao, D., Li, J., Liang, X., Li, J., Chang, A., Henry, V. K., Lan, Z., Spring, D. J., Rao, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.003 · Cited by 339
Self-citationAdvances in local therapy for glioblastoma — taking the fight to the tumour
van Solinge, T. S., Nieland, L., Chiocca, E. A., & Broekman, M. L. D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00621-0 · Cited by 334
Glioma Stem Cells: A Midterm Exam
Stiles, C. D., & Rowitch, D. H. (2008) · Neuron · doi:10.1016/j.neuron.2008.05.031 · Cited by 330
Self-citationPDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
Östman, A. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.002 · Cited by 326
BMI1 Sustains Human Glioblastoma Multiforme Stem Cell Renewal
Abdouh, M., Facchino, S., Chatoo, W., Balasingam, V., Ferreira, J., & Bernier, G. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0968-09.2009 · Cited by 326
Hoelzinger, D. B., Mariani, L., Weis, J., Woyke, T., Berens, T. J., McDonough, W., Sloan, A., Coons, S. W., & Berens, M. E. (2005) · Neoplasia · doi:10.1593/neo.04535 · Cited by 323
The induction of autophagy by γ‐radiation contributes to the radioresistance of glioma stem cells
Lomonaco, S. L., Finniss, S., Xiang, C., DeCarvalho, A., Umansky, F., Kalkanis, S. N., Mikkelsen, T., & Brodie, C. (2009) · International Journal of Cancer · doi:10.1002/ijc.24402 · Cited by 322
Liu, M., Dai, B., Kang, S.-H., Ban, K., Huang, F.-J., Lang, F. F., Aldape, K. D., Xie, T.-X., Pelloski, C. E., Xie, K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2912 · Cited by 314
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Eskilsson, E., Røsland, G. V., Solecki, G., Wang, Q., Harter, P. N., Graziani, G., Verhaak, R. G. W., Winkler, F., Bjerkvig, R., & Miletic, H. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox191 · Cited by 310
The Molecular and Genetic Basis of Neurological Tumours
Zhu, Y., & Parada, L. F. (2002) · Nature Reviews Cancer · doi:10.1038/nrc866 · Cited by 309
van den Boom, J., Wolter, M., Kuick, R., Misek, D. E., Youkilis, A. S., Wechsler, D. S., Sommer, C., Reifenberger, G., & Hanash, S. M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63463-3 · Cited by 307
Raica, M., & Cimpean, A. M. (2010) · Pharmaceuticals · doi:10.3390/ph3030572 · Cited by 304
Hovinga, K. E., Shimizu, F., Wang, R., Panagiotakos, G., Van Der Heijden, M., Moayedpardazi, H., Correia, A. S., Soulet, D., Major, T., Menon, J., et al. (2010) · Stem Cells · doi:10.1002/stem.429 · Cited by 302
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
Agarwal, S., Sane, R., Oberoi, R., Ohlfest, J. R., & Elmquist, W. F. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001888 · Cited by 292
Inhibition of tumor angiogenesis by cannabinoids
Blázquez, C., Casanova, M. L., Planas, A., Gómez del Pulgar, T., Villanueva, C., Fernández‐Aceñero, M. J., Aragonés, J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0795fje · Cited by 292
Amantini, C., Mosca, M., Nabissi, M., Lucciarini, R., Caprodossi, S., Arcella, A., Giangaspero, F., & Santoni, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04582.x · Cited by 280
Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas
Kwon, C.-H., Zhao, D., Chen, J., Alcantara, S., Li, Y., Burns, D. K., Mason, R. P., Lee, E. Y.-H. P., Wu, H., & Parada, L. F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6867 · Cited by 270
Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic Development
Zong, H., Parada, L. F., & Baker, S. J. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020610 · Cited by 269
The Pathobiology of Glioma Tumors
Gladson, C. L., Prayson, R. A., & Liu, W. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102109 · Cited by 254
Facchino, S., Abdouh, M., Chatoo, W., & Bernier, G. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1634-10.2010 · Cited by 253
EHD proteins: key conductors of endocytic transport
Naslavsky, N., & Caplan, S. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.10.003 · Cited by 237
An Unexpected Role for Ion Channels in Brain Tumor Metastasis
Sontheimer, H. (2008) · Experimental Biology and Medicine · doi:10.3181/0711-mr-308 · Cited by 231
Sunayama, J., Matsuda, K.-I., Sato, A., Tachibana, K., Suzuki, K., Narita, Y., Shibui, S., Sakurada, K., Kayama, T., Tomiyama, A., et al. (2010) · Stem Cells · doi:10.1002/stem.521 · Cited by 218
Dasari, V. R., Kaur, K., Velpula, K. K., Gujrati, M., Fassett, D., Klopfenstein, J. D., Dinh, D. H., & Rao, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010350 · Cited by 151
RetractedFerraris, C., Cavalli, R., Panciani, P. P., & Battaglia, L. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231479 · Cited by 131
Integrative multi-omics module network inference with lemon-tree
Bonnet, E., Calzone, L., & Michoel, T. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003983 · Cited by 98
Cellular origin of glioblastoma and its implication in precision therapy
Yao, M., Li, S., Wu, X., Diao, S., Zhang, G., He, H., Bian, L., & Lu, Y. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.159 · Cited by 94
Frequent LOH at Chromosome 12q22‐23 and Apaf‐1 Inactivation in Glioblastoma
Watanabe, T., Hirota, Y., Arakawa, Y., Fujisawa, H., Tachibana, O., Hasegawa, M., Yamashita, J., & Hayashi, Y. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00474.x · Cited by 55
Mora, R., Dokic, I., Kees, T., Hüber, C. M., Keitel, D., Geibig, R., Brügge, B., Zentgraf, H., Brady, N. R., & Régnier‐Vigouroux, A. (2010) · Glia · doi:10.1002/glia.21013 · Cited by 55
Targeting miR-21 in glioma: a small RNA with big potential
Moore, L. M., & Zhang, W. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.527334 · Cited by 51
Revisiting the role of p53 in primary and secondary glioblastomas.
(2006) · PubMed · Cited by 51
Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma
Ciznadija, D., Liu, Y., Pyonteck, S. M., Holland, E. C., & Koff, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1031 · Cited by 44
XU, G., GUO, Y., SENG, Z., CUI, G., & QU, J. (2015) · Oncology Reports · doi:10.3892/or.2015.4174 · Cited by 35
“Glioma, which is refractory to tumor therapies with high mortality and morbidity worldwide, is the most frequent intracranial tumor in humans (1,2).”
BackgroundDjuzenova, C. S., Fiedler, V., Memmel, S., Katzer, A., Hartmann, S., Krohne, G., Zimmermann, H., Scholz, C.-J., Polat, B., Flentje, M., et al. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.013 · Cited by 34
Cannabinoid receptor systems: therapeutic targets for tumour intervention.
Jones, S., & Howl, J. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.749 · Cited by 13
Deciphering Cancer Complexities in Genetically Engineered Mice
SIMIN, K., HILL, R., SONG, Y., ZHANG, Q., BASH, R., CARDIFF, R. D., YIN, C., XIAO, A., McCARTHY, K., & DYKE, T. V. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.038 · Cited by 8
“%) mutations (Louis and Cavenee 1997; Maher et al. 2001; Reilly and Jacks 2001).”
Metadata
- Authors
- Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2001-06-01
- Volume
- 15
- Issue
- 11
- Pages
- 1311-1333
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2114998237
- Cited by
- 1,229
- References
- 195
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.